334 related articles for article (PubMed ID: 32350119)
21. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant.
Shibaki A; Katz SI
Exp Dermatol; 2002 Apr; 11(2):126-34. PubMed ID: 11994139
[TBL] [Abstract][Full Text] [Related]
22. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
[TBL] [Abstract][Full Text] [Related]
23. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
Graham BS; McElrath MJ; Keefer MC; Rybczyk K; Berger D; Weinhold KJ; Ottinger J; Ferarri G; Montefiori DC; Stablein D; Smith C; Ginsberg R; Eldridge J; Duerr A; Fast P; Haynes BF;
PLoS One; 2010 Aug; 5(8):e11995. PubMed ID: 20706632
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
26. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.
Schaefer JT; Patterson JW; Deacon DH; Smolkin ME; Petroni GR; Jackson EM; Slingluff CL
J Transl Med; 2010 Aug; 8():79. PubMed ID: 20727190
[TBL] [Abstract][Full Text] [Related]
27. Oral immunization of mice with Omp31-loaded
Abkar M; Fasihi-Ramandi M; Kooshki H; Sahebghadam Lotfi A
Int J Nanomedicine; 2017; 12():8769-8778. PubMed ID: 29263667
[TBL] [Abstract][Full Text] [Related]
28. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
29. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
Melssen MM; Fisher CT; Slingluff CL; Melief CJM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
[TBL] [Abstract][Full Text] [Related]
30. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Speiser DE; Liénard D; Rufer N; Rubio-Godoy V; Rimoldi D; Lejeune F; Krieg AM; Cerottini JC; Romero P
J Clin Invest; 2005 Mar; 115(3):739-46. PubMed ID: 15696196
[TBL] [Abstract][Full Text] [Related]
31. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Montanide adjuvants, IMS 3012 (Nanoparticle), ISA 206 and ISA 35 (Emulsion based) along with incomplete Freund's adjuvant for hyperimmunization of equines used for production of polyvalent snake antivenom.
Waghmare A; Deopurkar RL; Salvi N; Khadilkar M; Kalolikar M; Gade SK
Vaccine; 2009 Feb; 27(7):1067-72. PubMed ID: 19100805
[TBL] [Abstract][Full Text] [Related]
33. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
[TBL] [Abstract][Full Text] [Related]
34. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine.
Johansson J; Hellman L
Vaccine; 2007 Feb; 25(9):1676-82. PubMed ID: 17150285
[TBL] [Abstract][Full Text] [Related]
35. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
[TBL] [Abstract][Full Text] [Related]
36. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
[TBL] [Abstract][Full Text] [Related]
37. A clinically applicable adjuvant for an atherosclerosis vaccine in mice.
Kobiyama K; Vassallo M; Mitzi J; Winkels H; Pei H; Kimura T; Miller J; Wolf D; Ley K
Eur J Immunol; 2018 Sep; 48(9):1580-1587. PubMed ID: 29932463
[TBL] [Abstract][Full Text] [Related]
38. Montanide ISA 71 VG is Advantageous to Freund's Adjuvant in Immunization Against S. aureus Infection of Mice.
Klimka A; Michels L; Glowalla E; Tosetti B; Krönke M; Krut O
Scand J Immunol; 2015 May; 81(5):291-7. PubMed ID: 25689117
[TBL] [Abstract][Full Text] [Related]
39. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE
Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235
[TBL] [Abstract][Full Text] [Related]
40. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.
Clancy-Thompson E; King LK; Nunnley LD; Mullins IM; Slingluff CL; Mullins DW
Cancer Immunol Res; 2013 Nov; 1(5):332-9. PubMed ID: 24377099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
